🧪 ALMS: $1.9M of Puts on a Stock Up More Than Fourfold — And the Readout May Land After They Expire

📅 2026-08-13 | 🤝 Floor Block Detected

---

🎯 The Quick Take

At 14:25:50 ET a desk bought 4,276 September-18 $20 puts at $4.40 in Alumis — ≈$1.88 million against prior open interest of one contract. A provably new position.

The price is the story. With the stock at ≈$24.28, a $20 put is out of the money — every cent of that $4.40 is time value, ≈18% of the share price for five weeks. Puts do not cost that unless the market expects something violent.

It does. The option market is pricing an implied move of ±38.23% by August 21 — eight days away — and ±68.10% by September 18.

What it is bracing for: Alumis has guided its Phase 2b lupus topline to "3Q 2026." That quarter ends September 30. This option expires September 18. The bet is live for the readout — unless the company reports in the final twelve days of the quarter, in which case it expires first.

---

🏢 Company Overview

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune disorders. Its lead asset is envudeucitinib (formerly ESK-001), an oral TYK2 inhibitor in Phase 3 for plaque psoriasis.

Source: ALMS overview

The move is the context for everything. From a 52-week low of $3.76 to a high of $31.35, this stock is up ≈452% over one year and ≈173% year to date. Market capitalisation is up +590.9% — the gap between that and the price return reflects shares issued in a January 2026 offering that raised ≈$345.1 million gross.

A $3.09B valuation on $8.40M of revenue is not a judgement about today's business. It is a judgement about a drug.

---

💰 The Trade, in Plain English

Printed as a negotiated floor block — a manually worked trade with a known counterparty, not an aggressive sweep. The BUY label is reported rather than tape-proven, since a floor block takes no liquidity and leaves no aggressor signature.

The economics:

One tape detail worth flagging. Twenty-three seconds before this block, a smaller 276-lot printed on the lit market at $3.90, into a tight quote of $3.90 bid / $4.00 offered. The block then crossed at $4.40 — forty cents, or 10%, above that displayed offer.

On a negotiated floor trade that usually means the quoted market was too thin to absorb 4,276 contracts and the price reflects the size rather than a chase. But it is worth stating plainly: this buyer paid up over the visible market to get size done.

---

✅ RESOLVED — Opened, and Then Some

Updated 2026-08-14 pre-market. Resolving OPRA snapshot timestamped August 14 (reflects the August 13 close, after this print); baseline is the August 13 snapshot (reflects the August 12 close, before this print).

The line went from one contract to 5,050. The block we captured accounts for 4,276 of that; the remaining ≈773 contracts are additional put buying at the $20 strike that landed the same session beyond this print. Nothing matched against existing holders — at an open interest of one, nothing could.

That overshoot is worth noting on its own. More money went to the same strike than the single block suggested, and it did so the session before the August 14 earnings report. The article's central tension is unchanged: the lupus readout is guided to "3Q 2026" with no exact date, and the September 18 expiry may still land before it.

---

🤓 What This Actually Means — Plain English

Buying a put that is already below the stock price is a bet on a big fall, not a small one.

The stock is ≈$24.28. The strike is $20. The put only starts having value at expiry if the shares drop below $20 — and because $4.40 was paid for it, it only turns a profit below $15.60. That is a ≈36% decline in five weeks.

So why pay $4.40 for something that needs a 36% collapse? Because the market thinks a move of that size is entirely plausible. The implied move to September 18 is ±68.10%, with a lower bound of $7.75. Against that, a fall to $15.60 is not a long shot — it is inside the range the option market already considers normal.

And notice how precisely the strikes align. The breakeven of $15.60 sits almost exactly on the August 21 implied lower bound of $15.00. This buyer did not pick a round number. They picked the level the market itself prices as a one-move decline.

What could deliver it: the lupus data. Envudeucitinib has already succeeded in psoriasis — that is the news this stock has climbed on, and it is now behind the company. The next test is lupus, an indication with a long and unforgiving record of late-stage failures. A stock that has quadrupled on one indication carries an expansion premium that a lupus miss would remove.

That is the whole trade: a stock priced for success, facing a hard indication, with the answer due inside the quarter.

---

📈 Technical Setup

Year-to-Date Performance

ALMS is up ≈173% year to date and ≈452% over one year, from a 52-week low of $3.76. It closed −4.46% at $24.41 on the day this trade printed, and sits below the $31.35 52-week high.

🔵🟠 Gamma-Based Support & Resistance

The chain produced no material gamma levels, and we are not going to invent any. Only six strikes carry meaningful open interest — $25, $27, $30, $31, $40 and $45.

Look at that list again: every single one is above the current price. There is no meaningful open interest below spot at all — which is exactly why a $20 put with one contract outstanding was available to be opened in size. Positioning in this name has been entirely to the upside, and this trade is the first substantial expression of the other view.

🎯 Implied Move

A ±38% move priced into eight days is extraordinary, and it is the clearest evidence that the market expects a binary event imminently — starting with tomorrow's earnings call.

---

🎪 Catalysts — Earnings Tomorrow, Lupus Data "3Q 2026"

The alignment is genuinely uncomfortable, and it deserves to be said rather than smoothed over. The lupus readout is guided to "3Q 2026" — July 1 through September 30. The option expires September 18. So the trade covers the guided window for all but its final twelve days, and companies frequently report late within a guided quarter. If the data slips to the last week of September, this position expires before the event it was built for.

That makes tomorrow's earnings call matter beyond the numbers — it is the most likely place for the timing to be narrowed.

What has already happened is the bullish half of the story. On March 28 Alumis reported ONWARD1 and ONWARD2 Phase 3 topline with PASI 90 of 68.0% and 62.1%. On August 10 — three days before this trade — the ONWARD3 48-week extension showed 75% PASI 90 and 54% PASI 100, which the company positions as the highest among oral therapies.

The psoriasis programme has read out, and it read out well. The share price reflects it. What remains ahead is the expansion bet.

Sources: Alumis overview and news · Alumis press releases

Keep the dates separate: the option expires September 18; earnings are August 14; the lupus topline is guided to the third quarter with no announced date; the NDA is fourth quarter.

---

👥 Four Ways to Read This Trade

🎲 The YOLO trader

This is the high-convexity structure you usually want — a single out-of-the-money put, maximum loss capped at the premium, ≈4.5x the risk available on a move to the implied lower bound. But respect what you are paying: ≈18% of the share price in pure time value, on an option whose defining catalyst is guided to a quarter, not a date. If the readout slips past September 18, you lose everything while being directionally right. Timing risk here is not a footnote — it is the main risk.

📈 The swing trader

Tomorrow's call is the event, and the single thing to listen for is any narrowing of the "3Q 2026" lupus guidance. The chain gives you nothing to lean on — no gamma support, no resistance, and no meaningful open interest below spot at all. That absence cuts both ways: no structural floor beneath the price, and no dealer positioning to fade. Against a ±38% eight-day implied move, position sizes should be small.

💰 The premium collector

The premiums look magnificent and that is precisely the warning. Selling this $20 put obligates you to buy a clinical-stage biotech at $20 that traded at $3.76 within the past year, days before an earnings call and inside a guided window for a lupus readout in an indication with a long history of failure. The ±68% implied move to September is not mispriced generosity — it is the market correctly charging for a binary. If you sell volatility here, do it defined-risk.

🌱 The beginner

Two lessons in one trade. First: an option's price tells you what the market expects. $4.40 for a put that is $4-plus below the stock is the market saying loudly that it expects a huge move — you can read fear directly off a price. Second, and more valuable: check whether the catalyst actually falls inside the expiration. Here the key event is guided to "the third quarter" and the option dies on September 18, twelve days before that quarter ends. Even a correct call on direction loses if the timing misses. Always match the expiration date to the calendar.

---

⚠️ Honest Limits

• Direction is reported, not tape-proven. A negotiated floor block takes no liquidity, so there is no aggressor read. If this is a sale rather than a purchase, the position is a premium-collection bet that ALMS holds above $20 — and the interpretation inverts entirely.
• The opening is proven; the intent is not. One contract of prior open interest settles open-versus-close beyond doubt. It does not distinguish a directional bet from a hedge on shares held elsewhere, and this stock is up ≈450% — protecting a large gain is an entirely rational reason to buy this put.
• The block printed 10% above the displayed offer from 23 seconds earlier. We read that as size versus a thin quote rather than urgency, but it is an inference.
• No exact date exists for the lupus readout — the company guides to "3Q 2026." Anything narrower would be invention, and the twelve-day gap between expiry and quarter-end is a real, unresolvable risk to the position.
• Gamma levels are absent, not omitted — the chain returned no support or resistance, so none is asserted.
• A market-cap versus price-return discrepancy is unresolved: market cap is quoted +590.9% while the price return computes to ≈+452%. The January equity offering plausibly explains a gap in that direction, but we did not verify the magnitude and do not reconcile the two.
• Research gaps, disclosed: the search budget was exhausted, so this rests on direct page retrieval only. No filings were read — cash position, current runway and the net proceeds, pricing and share count of the January offering are unknown and deliberately not stated. Phase 2b lupus trial design (size, endpoints, comparator, powering) was not retrievable. Izokibep's status could not be verified and no claim is made about it. No short-interest figure was available. The August 14 earnings date comes from the overview page rather than a company release.
• Unknowable from the tape: who holds this, and whether an equity or credit position sits behind it.

Last updated: 2026-08-14 — next-day OPRA open interest resolved the put as an open, and then some — 1 → 5,050 against a 4,276-lot print (see the ✅ RESOLVED section).

This is market analysis and education, not investment advice. Options carry substantial risk of loss.